Would you offer adjuvant capecitabine to a patient with resected intrahepatic cholangiocarcinoma after being treated with neoadjuvant GAP chemotherapy?  

This is a good question without a clear right answer. In the randomized phase 3 BILCAP trial (Primrose et al., PMID 30922733), the per protocol analysis showed that adjuvant capecitabine improved overall survival compared to observation alone. However, this study excluded patients who had previous c...